Global /United States /Healthcare /Drug Manufacturers - Specialty & Generic /CANB
chevron_leftBack
Can B Corp. logo

Can B Corp.

CANB
OTCMKTS: CANB Delayed
0.0180USD 1.1%
As of 13 June 2026, Can B Corp. has a market cap of $1.62M USD, ranking #47627 globally and #6063 in the United States. It ranks #4220 in the Healthcare sector, and #327 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
47627
Country Rank
6063
Sector Rank
4220
Industry Rank
327
Key Stats
Market Cap
$1.62MUSD
Enterprise Value
$18.85MUSD
Revenue (TTM)
$1.03MUSD
EBITDA (TTM)
-$6.78MUSD
Net Income (TTM)
-$13.26MUSD
PS Ratio
1.6
PB Ratio
-0.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Marco Alfonsi open_in_new
Employees
12
Founded
2005
Website
nascentpharmaholdings.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1.1% 0% -11% -7.8% -45% 74%

News

Loading...

Markets

Exchange Ticker Price
OTC Markets
MIC: OTCM
PRIMARY
CANB
Can B Corp
ISIN: US13470W2026
Shares Out.:
75.842M1 Shares Float: 73.309M2
TV:
SA:
YF:
GF:
BA:
MS:
0.0180 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Can B Corp.

Can B Corp. engages in the protection and commercialization of cannabis patents. It produces superfood drink mix products under the Longevity brand name. The company was formerly known as Canbiola Inc. and changed its name to Can B Corp. in January 2020. Can B Corp. was incorporated in 2005 and is based in Hicksville, New York.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (United States)
Name
Market Cap diff.
PE
$29.56B
2M%
-
INDV
$2.07B
1.54B GBP
127K%
-
NDOI
$1.8B
111K%
0.4
$1.76B
108K%
-
$1.33B
82K%
-
$1.02B
63K%
12.1
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
PE
$36.75B
108.92B ILS
2M%
24.2
$15.84B
107.34B CNY
976K%
16.0
CIPLA
$11.16B
1.06T INR
687K%
23.4
LUPIN
$11.04B
1.05T INR
680K%
22.7
$9.09B
61.6B CNY
560K%
80.6
$8.74B
7.57B EUR
539K%
-
chevron_leftBack